| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB120-22711SS | |||
| Azide and BSA Free | NBP2-80859 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-30440SS | |||
| Azide and BSA Free | NBP2-80715 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-57940SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-51843SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24659SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-236SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-60046SS | |||
![Immunocytochemistry/Immunofluorescence: MUC-1 Antibody (SM3) [NB120-22711] - MCF7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-MUC1 [SM3] at 5 ug/ml overnight at 4C and detected with an anti-mouse IgG Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/MUC-1-Antibody-SM3-Immunocytochemistry-Immunofluorescence-NB120-22711-img0004.jpg "Immunocytochemistry/Immunofluorescence: MUC-1 Antibody (SM3) [NB120-22711] - MCF7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-MUC1 [SM3] at 5 ug/ml overnight at 4C and detected with an anti-mouse IgG Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Immunohistochemistry-Paraffin: MUC-1 Antibody (SM3) [NB120-22711] - IHC analysis of formalin fixed paraffin embedded tissue section of human breast cancer xenograft using MUC-1 antibody clone SM3 at 1:10 dilution. The xenograft section depicted a very specific and intense signal in the periphery of the cancer cells. The necrotic cells also developed a strong immune-positivity while the tumor stroma as well as the nuclei of cells were negative for immunostaining.](http://images.novusbio.com/fullsize/MUC-1-Antibody-SM3-Immunohistochemistry-Paraffin-NB120-22711-img0003.jpg)
![Flow Cytometry: MUC1 Antibody (SM3) - BSA Free [NB120-22711] - An intracellular stain was performed on MCF7 cells with MUC1 Antibody (SM3) NB120-22711AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/MUC1-Antibody-SM3-BSA-Free-Flow-Cytometry-NB120-22711-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: MUC-1 Antibody (SM3) [NB120-22711] - MUC-1 antibody was tested in MCF7 cells at 10 ug/ml using a Dylight 488 conjugated secondary antibody (Green). Actin (Red) and DNA (Blue) were counterstained using Phalloidin 568 and DAPI.](http://images.novusbio.com/fullsize/MUC-1-Antibody-SM3-Immunocytochemistry-Immunofluorescence-NB120-22711-img0001.jpg)
![Immunohistochemistry-Paraffin: MUC-1 Antibody (SM3) [NB120-22711] - IHC analysis of formalin fixed paraffin embedded tissue section of human breast cancer xenograft using MUC-1 antibody clone SM3 at 1:10 dilution. The xenograft section depicted a very specific and intense signal in the periphery of the cancer cells. The necrotic cells also developed a strong diffused immune-positivity while the tumor stroma as well as the nuclei of cells were negative for immunostaining.](http://images.novusbio.com/fullsize/MUC-1-Antibody-SM3-Immunohistochemistry-Paraffin-NB120-22711-img0002.jpg)
![Western Blot: EGLN3/PHD3 Antibody (EG188e/d5) [NBP1-30440] - PHD3 expression in SK-N-BE(2) whole cell lysates. Cells were treated in normoxia (left) and in hypoxia (right). Image from verified customer review.](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-EG188e-d5-Western-Blot-NBP1-30440-img0007.jpg "<b>Biological Strategies Validation. </b>Western Blot: EGLN3/PHD3 Antibody (EG188e/d5) [NBP1-30440] - PHD3 expression in SK-N-BE(2) whole cell lysates. Cells were treated in normoxia (left) and in hypoxia (right). Image from verified customer review.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry: EGLN3/PHD3 Antibody (EG188e/d5) [NBP1-30440] - Analysis of HIF Prolyl Hydroxylase 3 in human renal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-EG188e-d5-Immunohistochemistry-NBP1-30440-img0005.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: EGLN3/PHD3 Antibody (EG188e/d5) [NBP1-30440] - Analysis of HIF Prolyl Hydroxylase 3 in (1) Cobalt chloride treated COS-7 nuclear extracts and (2) Untreated COS-7 nuclear extracts.](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-EG188e-d5-Western-Blot-NBP1-30440-img0004.jpg)
![Simple Western: EGLN3/PHD3 Antibody (EG188e/d5) [NBP1-30440] - Lane view shows a specific band for PHD3/HIF Prolyl Hydroxylase 3 in 0.5 mg/ml of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-EG188e-d5-Simple-Western-NBP1-30440-img0008.jpg)
![Western Blot: Ubiquitin Antibody [NB300-129] - Analysis of HEK293 cell lysates using rabbit Ubiquitin antibody, dilution 1:5000 (Green), and mouse beta-Tubulin antibody, dilution 1:10000 (Red) used as a loading control. [1] protein standard (Red), [2] cells maintained in normal medium, [3] cells treated with proteasome inhibitor lactacystin (Lc) at 10uM for 16 hours. Lysed cells were lysed and the lysate subjected to electrophoresis on a 4-20% SDS-PAGE gel, then electrophoretically transferred to PVDF membranes. The smear detected above the 200kDa standard represents accumulations of ubiquitinated proteins in the Lc treated cells. The prominent band at ~8kDa corresponds to monoubiquitin.](http://images.novusbio.com/fullsize/Ubiquitin-Antibody-Western-Blot-NB300-129-img0009.jpg "Western Blot: Ubiquitin Antibody [NB300-129] - Analysis of HEK293 cell lysates using rabbit Ubiquitin antibody, dilution 1:5000 (Green), and mouse beta-Tubulin antibody, dilution 1:10000 (Red) used as a loading control. [1] protein standard (Red), [2] cells maintained in normal medium, [3] cells treated with proteasome inhibitor lactacystin (Lc) at 10uM for 16 hours. Lysed cells were lysed and the lysate subjected to electrophoresis on a 4-20% SDS-PAGE gel, then electrophoretically transferred to PVDF membranes. The smear detected above the 200kDa standard represents accumulations of ubiquitinated proteins in the Lc treated cells. The prominent band at ~8kDa corresponds to monoubiquitin.")
![Immunocytochemistry/Immunofluorescence: Ubiquitin Antibody [NB300-129] - Analysis of HeLa cells stained with rabbit pAb to ubiquitin, NB300-129, dilution 1:1,000 in red, and costained with chicken pAb to vimentin, dilution 1:10,000, in green. The blue is DAPI staining of nuclear DNA. [A] Control HeLa cells maintained in normal medium, [B] HeLa cells treated with 10uM of the proteasome inhibitor lactacystin (Lc) for 24 hours. Proteasomal inhibition leads to formation of strongly ubiquitin positive cytoplasmic inclusions. Note the diffuse cytoplasmic ubiquitin staining in control cells and well defined ubiquitin positive inclusions in the Lc treated cells.](http://images.novusbio.com/fullsize/Ubiquitin-Antibody-Immunocytochemistry-Immunofluorescence-NB300-129-img0008.jpg)
![Immunohistochemistry-Paraffin: Ubiquitin Antibody [NB300-129] - IHC staining of Ubiquitin in human rectal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Ubiquitin-Antibody-Immunohistochemistry-Paraffin-NB300-129-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Ubiquitin Antibody [NB300-129] - Immunofluorescent staining of aggresomes of mouse L-cells treated with lactacysteine, using NB300-129.](http://images.novusbio.com/fullsize/Ubiquitin-Antibody-Immunocytochemistry-Immunofluorescence-NB300-129-img0001.jpg)
![Western Blot: MMP-9 Antibody [NBP1-57940] - Western blot of MMP-9. Image from verified customer review.](http://images.novusbio.com/fullsize/MMP-9-Antibody-Western-Blot-NBP1-57940-img0009.jpg "Western Blot: MMP-9 Antibody [NBP1-57940] - Western blot of MMP-9. Image from verified customer review.")
![Immunohistochemistry-Paraffin: MMP-9 Antibody [NBP1-57940] - Human prostate cancer was detected using HRP/AEC red color stain. Dilution: 2-15 ug/mL.](http://images.novusbio.com/fullsize/MMP-9-Antibody-Immunohistochemistry-Paraffin-NBP1-57940-img0005.jpg)
![Western Blot: MMP-9 Antibody [NBP1-57940] - Analysis of MMP-9 in mouse brain tumor lysate (GL261 implanted mouse glioma tissue, 40 ug/lane) using anti-MMP-9 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/MMP-9-Antibody-Western-Blot-NBP1-57940-img0004.jpg)
![Western Blot: MMP-9 Antibody [NBP1-57940] - HeLa cell lysate. Antibody at 1.25 ug/mL.](http://images.novusbio.com/fullsize/MMP-9-Antibody-Western-Blot-NBP1-57940-img0006.jpg)
![Western Blot: MMP-9 Antibody [NBP1-57940] - Human Fetal Lung. Antibody at 1.0 ug/mL.](http://images.novusbio.com/fullsize/MMP-9-Antibody-Western-Blot-NBP1-57940-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Aurora A Antibody [NBP1-51843] - HeLa cells were fixed and permeabilized for 10 minutes using -20C MeOH. The cells were incubated with anti- (NBP1-51843) at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution overnight at 4C and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-51843-img0012.jpg "Immunocytochemistry/Immunofluorescence: Aurora A Antibody [NBP1-51843] - HeLa cells were fixed and permeabilized for 10 minutes using -20C MeOH. The cells were incubated with anti- (NBP1-51843) at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution overnight at 4C and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Simple Western: Aurora A Antibody [NBP1-51843] - Simple Western lane view shows a specific band for Aurora A in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system.](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Simple-Western-NBP1-51843-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: Aurora A Antibody [NBP1-51843] - IF Confocal analysis of HeLa cells using Aurora A antibody (NBP1-51843, 1:10). An Alexa Fluor 488-conjugated Goat to rabbit IgG was used as secondary antibody (green). Actin filaments were labeled with Alexa Fluor 568 phalloidin (red). DAPI was used to stain the cell nuclei (blue).](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-51843-img0008.jpg)
![Western Blot: Aurora A Antibody [NBP1-51843] - WB detection of Aurora A in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Western-Blot-NBP1-51843-img0011.jpg)
![Immunohistochemistry: Aurora A Antibody [NBP1-51843] - IHC staining of Aurora A in mouse brain.](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Immunohistochemistry-NBP1-51843-img0003.jpg)
![Simple Western: Aurora A Antibody - BSA Free [NBP1-51843] - Analysis of protein expression post-drug treatment. (A) CHLA-10 and (B) TC-71 cells treated with drugs were assessed for changes in protein expression 24 h post-treatment via capillary electrophoresis-based Wes analysis. Increased protein levels of KIF11, p-KIF11Thr926 AURKA, and p-AURKAThr288 were observed for the drug combination group, whereas KIF15 levels were noticeably lower. Similarly, enhanced cleaved-PARP expression was observed with the combination treatment. The uncropped blots are shown in Figures S8 and S9. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/37894278 ), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-51843_rabbit-polyclonal-aurora-a-antibody-308202410445515.jpg)
![Simple Western: SOX9 Antibody [NBP2-24659] - Simple Western lane view shows a specific band for SOX9 in 0.5 mg/ml of Human Brain lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/SOX9-Antibody-Simple-Western-NBP2-24659-img0004.jpg "Simple Western: SOX9 Antibody [NBP2-24659] - Simple Western lane view shows a specific band for SOX9 in 0.5 mg/ml of Human Brain lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Immunohistochemistry: SOX9 Antibody [NBP2-24659] - Osteo-chondroprogenitor cells in the zone adjacent to the titanium plate surface are positive for Sox9 (arrows). Picture on the left represent Group 0.1, pictures on the right represent Group 0.6. 100-fold (c-d) magnification. PLoS One. 2018 Apr 6;13(4):e0195466. doi: 10.1371/journal.pone.0195466.](http://images.novusbio.com/fullsize/SOX9-Antibody-Immunohistochemistry-NBP2-24659-img0007.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: SOX9 Antibody [NBP2-24659] - 3'-Sialyllactose regulates anabolic and catabolic factor expression via Erk and NF-kB pathways. (C) Immunohistochemical staining of Sox9 in DMM-induced OA mice with administration of PBS and 3'-sialyllactose. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1111/jcmm.13292), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SOX9-Antibody-Immunohistochemistry-NBP2-24659-img0008.jpg)
![Immunohistochemistry-Frozen: SOX9 Antibody [NBP2-24659] - Feline optic nerve tissue section was incubated with antibody at 1:200 and further stained with Alexa secondary antibody. Image was captured with an epifluorescence microscope. This image was submitted via customer review.](http://images.novusbio.com/fullsize/SOX9-Antibody-Immunohistochemistry-Frozen-NBP2-24659-img0005.jpg)
![Western Blot: SOX9 Antibody [NBP2-24659] - Analysis of SOX9 in mouse embryo brain lysate in the 1) absence and 2) presence of immunizing peptide using SOX9 antibody at 2 ug/ml. Goat anti-rabbit Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/SOX9-Antibody-Western-Blot-NBP2-24659-img0003.jpg)
![Western Blot: SOX9 Antibody [NBP2-24659] - Analysis of SOX9 in human brain lysate in the 1) absence and 2) presence of immunizing peptide, 3) mouse brain and 4) rat brain lysate using SOX9 antibody at 3 ug/ml.](http://images.novusbio.com/fullsize/SOX9-Antibody-Western-Blot-NBP2-24659-img0002.jpg)
![Immunohistochemistry-Paraffin: SOX9 Antibody [NBP2-24659] - Analysis of SOX9 in formalin-fixed, paraffin-embedded mouse testis tissue using an isotype control (top left) and SOX9 antibody (bottom left, right) at 5 ug/ml.](http://images.novusbio.com/fullsize/SOX9-Antibody-Immunohistochemistry-Paraffin-NBP2-24659-img0001.jpg)
![Immunohistochemistry-Paraffin: SOX9 Antibody [NBP2-24659] - 3′‐Sialyllactose regulates anabolic & catabolic factor expression via Erk & NF‐ kappa B pathways. (A, B) Chondrocytes were pre‐treated with different concentrations of 3′‐sialyllactose for 24 hrs prior to treatment with IL‐1 beta (5 ng/ml) for 10 min. Erk phosphorylation was measured by Western blotting (A, upper panel) & densitometry (A, lower panel). The protein level of I kappa B was detected by Western blotting (B, upper panel) & densitometry (B, lower panel). Erk was detected as a loading control. (C) Immunohistochemical staining of Sox9, I kappa B & pErk in DMM‐induced OA mice with administration of PBS & 3′‐sialyllactose. (D) Schematic diagram of the signalling pathway leading to Sox9 activation & NF‐ kappa B inhibition by 3′‐sialyllactose. Values represent the means ± S.E.M. *P < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28782172), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24659_rabbit-polyclonal-sox9-antibody-310202416113513.jpg)
![Western Blot: Survivin [p Thr34] Antibody [NB500-236] - Western blot analysis using [NB500-236]. Lane 1: Phosphorylated Survivin protein and Lane 2: Non-phosphorylated Survivin protein. Note: theoretical molecular weight of Survivin Antibody: 16 kDa.](http://images.novusbio.com/fullsize/Survivin-[p-Thr34]-Antibody-Western-Blot-NB500-236-img0003.jpg "Western Blot: Survivin [p Thr34] Antibody [NB500-236] - Western blot analysis using [NB500-236]. Lane 1: Phosphorylated Survivin protein and Lane 2: Non-phosphorylated Survivin protein. Note: theoretical molecular weight of Survivin Antibody: 16 kDa.")
![Immunocytochemistry/Immunofluorescence: Survivin [p Thr34] Antibody [NB500-236] - Immunocytochemical analysis using Survivin [p Thr34] Antibody [NB500-236] in HeLa cells with FITC (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/Survivin-[p-Thr34]-Antibody-Immunocytochemistry-Immunofluorescence-NB500-236-img0004.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: Survivin [p Thr34] Antibody [NB500-236] - Combination therapy with TiOxNPs and IR suppressed the aggressiveness of xenografts in dissociated MIA PaCa sphere cell-bearing mice. Western blot for expression of Survivin [p Thr34] (NB500-236) in xenografts of dissociated MIA PaCa sphere-bearing cells treated with TiOxNPs and/or irradiation. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35428310/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nb500-236_rabbit-polyclonal-survivin-p-thr34-antibody-2552023151499.jpg)
![Western Blot: Survivin [p Thr34] Antibody [NB500-236] - Combination therapy with TiOxNPs & IR suppressed the aggressiveness of xenografts in dissociated MIA PaCa sphere cell-bearing mice. A HE staining & IHC analysis of p-H2AX, c-caspase-3, ki67, PCNA, snail/Slug, & vimentin in the indicated groups. Scale bar = 50 μm. n=5. B Western blot for expression of p-H2AX, c-caspase-3, p-survivin, snail/Slug, & vimentin in xenografts of dissociated MIA PaCa sphere-bearing cells treated with TiOxNPs and/or irradiation. C In vivo apoptosis marker TUNEL assay in xenografts of dissociated MIA PaCa sphere-bearing cells treated with TiOxNPs and/or irradiation. n=5. Data are shown as the mean ± standard deviation. ns, not significant. ****p < 0.0001. Scale bar = 200 μm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35428310), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-236_rabbit-polyclonal-survivin-p-thr34-antibody-31020241539717.jpg)
![Survivin [p Thr34] was detected in immersion fixed HeLa human cervix adenocarcinoma cell line using Rabbit anti-Survivin [p Thr34] Antigen Affinity Purified Polyclonal Antibody (Catalog # NB500-236) at 2.0 µg/mL overnight at 4C. Cells were stained using DyLight 488-conjugated Anti-Rabbit IgG (H+L) Cross-Absorbed Secondary Antibody (green), and counterstained with DAPI (blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/antibody/nb500-236_rabbit-polyclonal-survivin-p-thr34-antibody-immunocytochemistry-immunofluorescence-2662025104450..jpg)
![Survivin [p Thr34] was detected in immersion fixed NIH-3T3 Mouse fibroblast cell line using Rabbit anti Survivin [p Thr34] Antigen Affinity Purified Polyclonal Antibody (Catalog # NB500-236) at 2.0 µg/mL overnight at 4C. Cells were stained using DyLight 488-conjugated Anti-Rabbit IgG (H+L) Cross-Absorbed Secondary Antibody (green), and counterstained with DAPI (blue). Cells in various stages of mitosis were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/antibody/nb500-236_rabbit-polyclonal-survivin-p-thr34-antibody-immunocytochemistry-immunofluorescence-2662025104618..jpg)
![Western Blot: MUC1 Antibody - BSA Free [NBP1-60046] - MUC1 Antibody [NBP1-60046] - C57BL/6 Muc1 KO mice and WT mice were undergoing intranasal instillation of 75 ug of lipopolysaccharide (LPS) at day 1. Between days 2 and 3, animals were exposed to cigarette smoke (or control air) of 6 cigarettes followed by 8 cigarettes (or control air) at days 4 and 5, and 10 cigarettes (or control air) at day 6. Vehicle or dexamethasone at 3 mg/kg/day and 10 mg/kg/day was administered orally once a day between day 1 and 6. Animals were sacrificed at day 6 and lungs were homogenized to analyze protein expression of Muc1 cytoplasmic tail (CT). Protein expression was normalized to B-actin. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0927-4) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/MUC1-Antibody-Knockout-Validated-NBP1-60046-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: MUC1 Antibody - BSA Free [NBP1-60046] - MUC1 Antibody [NBP1-60046] - C57BL/6 Muc1 KO mice and WT mice were undergoing intranasal instillation of 75 ug of lipopolysaccharide (LPS) at day 1. Between days 2 and 3, animals were exposed to cigarette smoke (or control air) of 6 cigarettes followed by 8 cigarettes (or control air) at days 4 and 5, and 10 cigarettes (or control air) at day 6. Vehicle or dexamethasone at 3 mg/kg/day and 10 mg/kg/day was administered orally once a day between day 1 and 6. Animals were sacrificed at day 6 and lungs were homogenized to analyze protein expression of Muc1 cytoplasmic tail (CT). Protein expression was normalized to B-actin. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0927-4) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Knockout Validated: MUC1 Antibody [NBP1-60046] - Dexamethasone induces Muc1-CT nuclear translocation and co-localization with GRa in bronchial epithelium of WT mice but not in MUC1 KO mice. C57BL/6 Muc1 KO mice and WT mice were undergoing dexamethasone 10 mg/kg/day (orally) for 6 days. Animals were sacrificed at day 6 and lungs were fixed in paraformaldehyde (4%) for 48 h and embedded. Lung slices were immunostained with MUC1-cytoplasmic tail (CT) (red) and glucocorticoid receptor alpha (GRa) antibodies (green) with rhodamine/fluorescein secondary antibodies. DAPI was used to mark cell nucleus. Representative con-focal images are showed. Scale bar: 5 um. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0927-4) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/MUC1-Antibody-Knockout-Validated-NBP1-60046-img0013.jpg)
![Western Blot: MUC-1 Antibody [NBP1-60046] - Total protein from mouse 3T3 cells and human HeLa cells, stomach and colon was separated on a 4-15% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-MUC-1 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/MUC-1-Antibody-Western-Blot-NBP1-60046-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: MUC1 Antibody [NBP1-60046] - Tested in HeLa cells at a 1:50 dilution against DyLight 488 (Green). Cells were counterstained for alpha-tubulin against DyLight 550 (Red) and mounted in DAPI fluoromount (Blue).](http://images.novusbio.com/fullsize/MUC-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-60046-img0010.jpg)
![Immunohistochemistry-Paraffin: MUC1 Antibody [NBP1-60046] - Human kidney lysate tissue at an antibody concentration of 4-8ug/ml.](http://images.novusbio.com/fullsize/MUC1-Antibody-Immunohistochemistry-Paraffin-NBP1-60046-img0003.jpg)
![Immunohistochemistry-Paraffin: MUC1 Antibody [NBP1-60046] - Pig stomach.](http://images.novusbio.com/fullsize/MUC1-Antibody-Immunohistochemistry-Paraffin-NBP1-60046-img0007.jpg)
![Immunohistochemistry-Paraffin: MUC1 Antibody [NBP1-60046] - Pig stomach.](http://images.novusbio.com/fullsize/MUC1-Antibody-Immunohistochemistry-Paraffin-NBP1-60046-img0008.jpg)
![Immunohistochemistry-Paraffin: MUC1 Antibody [NBP1-60046] - Human stomach.](http://images.novusbio.com/fullsize/MUC1-Antibody-Immunohistochemistry-Paraffin-NBP1-60046-img0009.jpg)
![Immunocytochemistry/ Immunofluorescence: MUC1 Antibody - BSA Free [NBP1-60046] - Dexamethasone induces Muc1-CT nuclear translocation & co-localization with GR alpha in bronchial epithelium of WT mice but not in MUC1 KO mice. C57BL/6 Muc1 KO mice & WT mice were undergoing dexamethasone 10 mg/kg/day (orally) for 6 days. Animals were sacrificed at day 6 & lungs were fixed in paraformaldehyde (4%) for 48 h & embedded in Tissue-Tek® OCT™ cryosectioning compound. Lung slices were immunostained with MUC1-cytoplasmic tail (CT) & glucocorticoid receptor alpha (GR alpha ) antibodies with rhodamine/fluorescein secondary antibodies. DAPI was used to mark cell nucleus. Representative con-focal images are showed. Scale bar: 5 μm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30458870), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-60046_rabbit-polyclonal-muc1-antibody-310202415363741.jpg)
![Chromatin Immunoprecipitation: MUC1 Antibody - BSA Free [NBP1-60046] - MUC1 binds RIPK1 to mediate the RIPK1/RIPK3 pathway. (a,b) MUC1 knockdown by MUC1‐siRNA or NC‐siRNA were assayed in 16HBE cells following stimulation with TNF‐ alpha (300 ng/ml). After 24 hr of stimulation, RIPK3 & RIPK1 protein levels were measured by western blot analysis. (c,d) Normal 16HBE cells were treated with TNF‐ alpha for 24 hr, & the interaction between MUC1‐CT & RIPK1/RIPK3 were confirmed by immunoprecipitation. Data are expressed as means ± SD & were analyzed by one‐way analysis of variance, *p < 0.05. NC group (transfected with NC siRNA); MUC1‐siRNA group (transfected with MUC1‐siRNA). 16HBE: human bronchial epithelial; IB: immunoblotting; IP: immunoprecipitation; RIPK1: receptor‐interacting protein kinase‐1; RIPK3: receptor‐interacting protein kinase‐3; NC: negative control; siRNA: small interfering RNA; TNF‐ alpha : tumor necrosis factor‐ alpha Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30666647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-60046_rabbit-polyclonal-muc1-antibody-310202416161843.jpg)
![Western Blot: MUC1 Antibody - BSA Free [NBP1-60046] - MUC1 downregulation & TLR4 overexpression in lung tissue from heavy smokers & COPD patients. Lung tissue from healthy (n = 10), smokers (n = 11) & COPD patients (n = 13) were analysed. MUC1 mRNA gene expression in lung tissue homogenates (a), bronchial epithelial cells (b) & sputum neutrophils (c). d MUC1-CT protein expression in lung homogenates.TLR4 mRNA gene expression in lung tissue homogenates (e), bronchial epithelial cells (f) & sputum neutrophils (g). h MUC1-CT protein expression in lung homogenates. i Correlation of TL4 & MUC1 gene expression in lung tissue from smokers & COPD patients. j Correlation of FEV1% & MUC1 gene expression in lung tissue from smokers & COPD patients. Gene expression was analyzed by real time PCR using the 2-delta Ct as described in methods. Protein expression was analyzed by western blot. Representative western blot are showed. Data are presented as median with interquartile range. “P” exact values were obtained following Kruskal Wallis test. FEV1%: forced expiratory volume in 1 s Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30458870), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-60046_rabbit-polyclonal-muc1-antibody-310202416165614.jpg)
![Chromatin Immunoprecipitation: MUC1 Antibody - BSA Free [NBP1-60046] - MUC1 binds RIPK1 to mediate the RIPK1/RIPK3 pathway. (a,b) MUC1 knockdown by MUC1‐siRNA or NC‐siRNA were assayed in 16HBE cells following stimulation with TNF‐ alpha (300 ng/ml). After 24 hr of stimulation, RIPK3 & RIPK1 protein levels were measured by western blot analysis. (c,d) Normal 16HBE cells were treated with TNF‐ alpha for 24 hr, & the interaction between MUC1‐CT & RIPK1/RIPK3 were confirmed by immunoprecipitation. Data are expressed as means ± SD & were analyzed by one‐way analysis of variance, *p < 0.05. NC group (transfected with NC siRNA); MUC1‐siRNA group (transfected with MUC1‐siRNA). 16HBE: human bronchial epithelial; IB: immunoblotting; IP: immunoprecipitation; RIPK1: receptor‐interacting protein kinase‐1; RIPK3: receptor‐interacting protein kinase‐3; NC: negative control; siRNA: small interfering RNA; TNF‐ alpha : tumor necrosis factor‐ alpha Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30666647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-60046_rabbit-polyclonal-muc1-antibody-310202416175235.jpg)
![Simple Western: VPS34 Antibody [NB110-87320] - Simple Western lane view shows a specific band for VPS34 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/VPS34-Antibody-Simple-Western-NB110-87320-img0006.jpg "Simple Western: VPS34 Antibody [NB110-87320] - Simple Western lane view shows a specific band for VPS34 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![<b>Genetic Strategies Validation. </b>Western Blot: VPS34 Antibody [NB110-87320] - ATG7 depleted SKBR3 cells show increased sensitivity to ATRA and the RARalpha agonist AM580. RARalpha , ATG5 and VPS34 Western blot analysis of control and the respective SKBR3 knockdown cells. GAPDH was used as a loading control. Image collected and cropped by CiteAb from the following publication (), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VPS34-Antibody-Knockdown-Validated-NB110-87320-img0007.jpg)
![Western Blot: VPS34 Antibody [NB110-87320] - HepG2 whole cell lysates.](http://images.novusbio.com/fullsize/VPS34-Antibody-Western-Blot-NB110-87320-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: VPS34 Antibody [NB110-87320] - VPS34 antibody was tested at 1:200 in HeLa cells with FITC (green). Nuclei (Blue) were counterstained with Dapi (blue).](http://images.novusbio.com/fullsize/VPS34-Antibody-Immunocytochemistry-Immunofluorescence-NB110-87320-img0005.jpg)
![Western Blot: VPS34 Antibody [NB110-87320] - Celastrol regulates autophagy- & mitophagy-related gene expressions in neurons. SH-SY5Y cells treated with 0.1–1 μM celastrol for 4 h. (A) Real-time quantitative PCR results show that 1 μM celastrol treatment for 4 h enhanced mRNA expressions of phagophore induction genes Beclin 1 & Ambra1, phagophore elongation genes Atg7 & Atg12, & vacuole formation genes LC3A & Atg4B. (B) Western blot results of SH-SY5Y treated with 100–500 nM celastrol show celastrol (500 nM) increased in protein expressions of Beclin 1 & Vps34 (phagophore induction), Atg7 (phagophore elongation), LC3-II (vacuole formation), DJ-1, & PINK1 (mitophagy). Celastrol (500 nM) suppressed LRRK2 expression. (C) MPTP (10 mg/kg/day for 3 days, i.p.) but not celastrol (3 mg/kg/day for 3 days, i.p.) caused dopaminergic nerve terminal degeneration (tyrosine hydroxylase↓) & mitophagy inactivation (DJ-1↓ & PINK1↓) in the striatum of mice as compared to saline control. Celastrol cotreatment with MPTP reversed it as compared to MPTP. Data are given as the mean ± SEM (n = 3–5). p-value was determined using the Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test. * p < 0.05 compared with controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31906147), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-87320_rabbit-polyclonal-vps34-antibody-310202416205164.jpg)
![Western Blot: PBR Antibody [NB100-41398] - Staining of A431 cell lysate.(35 ug protein in RIPA buffer). Antibody at 0.3 ug/mL. Detected by chemiluminescence.](http://images.novusbio.com/fullsize/PBR-Antibody-Western-Blot-NB100-41398-img0011.jpg "Western Blot: PBR Antibody [NB100-41398] - Staining of A431 cell lysate.(35 ug protein in RIPA buffer). Antibody at 0.3 ug/mL. Detected by chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: PBR Antibody [NB100-41398] - Immunofluorescence analysis of paraformaldehyde fixed MCF7 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/PBR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-41398-img0010.jpg)
![Immunohistochemistry: PBR Antibody [NB100-41398] - Correlative TSPO immunohistochemistry in a primary human grade III astrocytoma xenotransplant, Tumor + White Matter Tract (40X). Image collected and cropped by CiteAb from the following publication (www.journals.plos.org/plosone/article?id=10.1371/journal.pone.0141659) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunohistochemistry-NB100-41398-img0013.jpg)
![Flow Cytometry: PBR Antibody [NB100-41398] - Flow cytometric analysis of paraformaldehyde fixed MCF7 cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/PBR-Antibody-Flow-Cytometry-NB100-41398-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: PBR Antibody [NB100-41398] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative cLontrol: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-41398-img0009.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Staining of paraffin embedded Human Colon. Antibody at 2.5 ug/mL. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunohistochemistry-Paraffin-NB100-41398-img0005.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Staining of paraffin embedded Human Kidney. Antibody at 5 ug/mL. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunohistochemistry-Paraffin-NB100-41398-img0007.jpg)
![Immunohistochemistry: PBR Antibody [NB100-41398] - Human tumor microarrays (TMAs). Pilocytic astrocytoma TSPO immunohistochemistry (A) and Glioblastoma multiforme TSPO immunohistochemistry (B). Image collected and cropped by CiteAb from the following publication (www.journals.plos.org/plosone/article?id=10.1371/journal.pone.0141659) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PBR-Antibody-Immunohistochemistry-NB100-41398-img0012.jpg)
![Immunohistochemistry: PBR Antibody [NB100-41398] - [18F]PBR06 selectivity in primary human grade IV glioblastoma xenotransplant.(A) Dynamic PET image (axial) pre-infusion of cold analog, with [18F]PBR06 uptake primarily confined to the tumor. (B) Dynamic PET image (axial) post-infusion, showing nearly total displacement of [18F]PBR06. (C) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue). (D) Correlative TSPO immunohistochemistry, Tumor + White Matter Tract (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-31020241534322.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Human tumor microarrays (TMAs).Pilocytic astrocytoma TSPO immunohistochemistry (A) & TSPO immunohistochemical scoring (C). Glioblastoma multiforme TSPO immunohistochemistry (B) & TSPO immunohistochemical scoring (D). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415304277.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Human tumor microarrays (TMAs).Pilocytic astrocytoma TSPO immunohistochemistry (A) & TSPO immunohistochemical scoring (C). Glioblastoma multiforme TSPO immunohistochemistry (B) & TSPO immunohistochemical scoring (D). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415392564.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Primary human grade IV glioblastoma xenotransplant.(A) Dynamic PET image (coronal) of advanced tumor in the right hemisphere of the brain with [18F]PBR06 uptake confined primarily to the tumor. Arrows indicate tumor & infiltration into left hemisphere. (B) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue) [30]. (C) Correlative TSPO immunohistochemistry, Tumor + White Matter Tract (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415371958.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Primary human grade III astrocytoma xenotransplant.(A) T2-weighted MRI (coronal) visualizes advanced tumor in the right hemisphere of the brain. (B) Correlative dynamic PET image (coronal) of same advanced tumor in the right hemisphere of the brain, with [18F]PBR06 uptake primarily confined to the tumor & co-localizing with tumor tissue visualized by MRI. Top arrows indicate tumor & infiltration into left hemisphere. (C) Fused MRI (A) PET (B) image. (D) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue). Correlative vimentin immunohistochemistry: (E) Gross; (F) Tumor + White Matter Tract (40X); (G) Tumor (40X). (H) Correlative dynamic PET image, axial view along yellow line in (B); arrows indicate tumor & infiltration into left hemisphere. Correlative TSPO immunohistochemistry: (I) Gross; (J) Tumor + White Matter Tract (40X); (K) Tumor (40X). (L) Dynamic PET image (axial) of control cohort. Correlative CD68 immunohistochemistry: (M) Gross; (N) Tumor + White Matter Tract (40X); (O) Tumor (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415535136.jpg)
![Immunohistochemistry-Paraffin: PBR Antibody [NB100-41398] - Primary human grade III astrocytoma xenotransplant.(A) T2-weighted MRI (coronal) visualizes advanced tumor in the right hemisphere of the brain. (B) Correlative dynamic PET image (coronal) of same advanced tumor in the right hemisphere of the brain, with [18F]PBR06 uptake primarily confined to the tumor & co-localizing with tumor tissue visualized by MRI. Top arrows indicate tumor & infiltration into left hemisphere. (C) Fused MRI (A) PET (B) image. (D) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue). Correlative vimentin immunohistochemistry: (E) Gross; (F) Tumor + White Matter Tract (40X); (G) Tumor (40X). (H) Correlative dynamic PET image, axial view along yellow line in (B); arrows indicate tumor & infiltration into left hemisphere. Correlative TSPO immunohistochemistry: (I) Gross; (J) Tumor + White Matter Tract (40X); (K) Tumor (40X). (L) Dynamic PET image (axial) of control cohort. Correlative CD68 immunohistochemistry: (M) Gross; (N) Tumor + White Matter Tract (40X); (O) Tumor (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-31020241612624.jpg)
![Immunohistochemistry: PBR Antibody [NB100-41398] - Primary human grade III astrocytoma xenotransplant.(A) T2-weighted MRI (coronal) visualizes advanced tumor in the right hemisphere of the brain. (B) Correlative dynamic PET image (coronal) of same advanced tumor in the right hemisphere of the brain, with [18F]PBR06 uptake primarily confined to the tumor & co-localizing with tumor tissue visualized by MRI. Top arrows indicate tumor & infiltration into left hemisphere. (C) Fused MRI (A) PET (B) image. (D) Time-activity curves of injected [18F]PBR06 in tumor (green) & contralateral brain (blue). Correlative vimentin immunohistochemistry: (E) Gross; (F) Tumor + White Matter Tract (40X); (G) Tumor (40X). (H) Correlative dynamic PET image, axial view along yellow line in (B); arrows indicate tumor & infiltration into left hemisphere. Correlative TSPO immunohistochemistry: (I) Gross; (J) Tumor + White Matter Tract (40X); (K) Tumor (40X). (L) Dynamic PET image (axial) of control cohort. Correlative CD68 immunohistochemistry: (M) Gross; (N) Tumor + White Matter Tract (40X); (O) Tumor (40X). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0141659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-41398_goat-polyclonal-pbr-antibody-310202415533823.jpg)
![Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NB100-59740] - (0.003ug/ml) staining of Mouse (A) and Rat (B) Liver lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/nb100-59740_goat-polyclonal-arginase-1-arg1-liver-arginase-antibody-1652023918335.jpg "Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NB100-59740] - (0.003ug/ml) staining of Mouse (A) and Rat (B) Liver lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.")
![Western Blot: FoxC1 Antibody [NB100-1268] - Left- Significant upregulation of Foxc1 mRNA in Ezh2-/- Tet-ON PyVmT endpoint tumours compared to wild-type tumours. Right- Immunoblot of Ezh2+/+ or Ezh2-/- Tet-ON PyVmT endpoint tumours for Foxc1 and Ezh2 levels. Vinculin loading control. *p<0.05, two tailed t-test. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Western-Blot-NB100-1268-img0018.jpg "<b>Biological Strategies Validation. </b>Western Blot: FoxC1 Antibody [NB100-1268] - Left- Significant upregulation of Foxc1 mRNA in Ezh2-/- Tet-ON PyVmT endpoint tumours compared to wild-type tumours. Right- Immunoblot of Ezh2+/+ or Ezh2-/- Tet-ON PyVmT endpoint tumours for Foxc1 and Ezh2 levels. Vinculin loading control. *p<0.05, two tailed t-test. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: FoxC1 Antibody [NB100-1268] - Paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary antibody at 10 ug/mL, 1 hr incubation, followed by Alexa Fluor 488 secondary antibody at 2 ug/mL, showing nuclear and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/FoxC1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-1268-img0015.jpg)
![<b>Orthogonal Strategies Validation. </b>Immunohistochemistry: FoxC1 Antibody [NB100-1268] - Representative images of formalin fixed paraffin-embedded tissue samples from human Luminal B tumours stained for FOXC1 and EZH2. Scale bar is 100um. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Immunohistochemistry-NB100-1268-img0016.jpg)
![Flow Cytometry: FoxC1 Antibody [NB100-1268] - Paraformaldehyde fixed HEK293 cells (blue line), permeabilized with 0.5% Triton. Primary antibody at 10 ug/mL, 1 hr incubation, followed by Alexa Fluor 488 secondary antibody at 2 ug/mL. IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Flow-Cytometry-NB100-1268-img0014.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: FoxC1 Antibody [NB100-1268] - Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 and treated with DMSO or GSK-126 (2uM for 72h). a-Tubulin was used as a loading control. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-018-04864-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxC1-Antibody-Knockdown-Validated-NB100-1268-img0017.jpg)
![Immunocytochemistry/ Immunofluorescence: FoxC1 Antibody [NB100-1268] - Breast Cancer subtype specificity of the EZH2/FOXC1 metastatic axis. a Representative images of formalin fixed paraffin-embedded tissue samples from human Luminal B tumours stained for FOXC1 & EZH2. Scale bar is 100 μm. b Significant negative correlation between FOXC1 transcript levels & EZH2 protein levels (Total intensity) quantified by immunofluorescence in human Luminal B patient samples (r = −0.52, p = 0.02). Eight different fields taken with a ×20 objective were quantified per sample. c Kaplan–Meier survival curve of relapse-free survival (RFS) of 1142 luminal B tumours with high or low FOXC1 (log rank p = 0.001). d Correlation between FOXC1 mRNA levels & the FOXC1 Signature in a cohort of 385 Luminal B patients from publicly available TCGA Breast Cancer data set. e Kaplan–Meier analysis of relapse-free survival of 1142 Luminal B tumours with high or low FOXC1 gene signature expression (log rank p = 0.0044). RFS relapse-free survival Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1268_goat-polyclonal-foxc1-antibody-310202415541964.jpg)
![Western Blot: FoxC1 Antibody [NB100-1268] - Ectopic expression of Foxc1 alters invasion but not proliferation. a Transwell invasion assay of PyVmT cells expressing exogenous Foxc1 or GFP. Experiments were performed three times, & results are displayed relative to untreated parental cell. *p < 0.05, Student’s two tailed t-tests. b CyQUANT assay measuring cellular proliferation of PyVmT cells expressing exogenous GFP or Foxc1. R.F.U relative fluorescence units. Data were normalized to the fluorescence values at time = 0. c Enumeration of lung lesions following the injection of PyVmT cells expressing exogenous Foxc1 or GFP in the tail vein of athymic nude mice. *p < 0.05, Student’s two tailed t-tests. Scale bar is 5 mm. d Left: Representative immunoblot showing Foxc1 expression in cells stably transduced with a control shRNA (shLacZ) or two independent shRNAs targeting Foxc1 & treated with DMSO or GSK-126 (2 μM for 72 h). alpha -Tubulin was used as a loading control. Right: Transwell invasion assay of PyVmT cells infected with shRNA targeting LacZ (control) or two different sequences targeting Foxc1. Cells were pre-treated with DMSO or GSK-126 (2 μM) for 72 h & assayed for their capacity to invade through Matrigel. All assays were performed in triplicate. *p < 0.05, Student’s two tailed t-tests Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29959321), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1268_goat-polyclonal-foxc1-antibody-3102024168211.jpg)